David Back

Summary

Affiliation: University of Liverpool
Country: UK

Publications

  1. ncbi request reprint Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response
    Alan Winston
    J Acquir Immune Defic Syndr 41:675-6. 2006
  2. doi request reprint The importance of drug-drug interactions in the DAA era
    David Back
    Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK Electronic address
    Dig Liver Dis 45:S343-8. 2013
  3. ncbi request reprint Darunavir: pharmacokinetics and drug interactions
    David Back
    Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
    Antivir Ther 13:1-13. 2008
  4. ncbi request reprint Therapeutic drug monitoring in HIV infection: current status and future directions
    David Back
    Pharmacology Research Laboratories, University of Liverpool, UK
    AIDS 16:S5-37. 2002
  5. ncbi request reprint An update on therapeutic drug monitoring for antiretroviral drugs
    David Back
    Pharmacology Research Laboratories, University of Liverpool, 70 Pembroke Street, Liverpool, USA
    Ther Drug Monit 28:468-73. 2006
  6. ncbi request reprint Pharmacokinetic drug interactions with nevirapine
    David Back
    Liverpool HIV Pharmacology Group, Pharmacology Research Laboratories, University of Liverpool, Pembroke Place, Liverpool L69 3GF, UK
    J Acquir Immune Defic Syndr 34:S8-14. 2003
  7. ncbi request reprint Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients
    Jennifer Ford
    Department of Pharmacology and Therapeutics, University of Liverpool, 70 Pembroke Place, Liverpool L69 3GF, and PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    J Antimicrob Chemother 58:1009-16. 2006
  8. doi request reprint Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach
    Marco Siccardi
    Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, 70 Pembroke Place, Liverpool, L69 3GF, UK
    Clin Pharmacokinet 52:583-92. 2013
  9. ncbi request reprint Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals
    Laura Dickinson
    Department of Pharmacology, University of Liverpool, Liverpool, UK
    Ther Drug Monit 29:361-7. 2007
  10. pmc Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies
    Alessandro Schipani
    Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
    J Acquir Immune Defic Syndr 62:60-6. 2013

Collaborators

Detail Information

Publications48

  1. ncbi request reprint Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response
    Alan Winston
    J Acquir Immune Defic Syndr 41:675-6. 2006
  2. doi request reprint The importance of drug-drug interactions in the DAA era
    David Back
    Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK Electronic address
    Dig Liver Dis 45:S343-8. 2013
    ....
  3. ncbi request reprint Darunavir: pharmacokinetics and drug interactions
    David Back
    Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
    Antivir Ther 13:1-13. 2008
    ....
  4. ncbi request reprint Therapeutic drug monitoring in HIV infection: current status and future directions
    David Back
    Pharmacology Research Laboratories, University of Liverpool, UK
    AIDS 16:S5-37. 2002
    ..However, TDM has been introduced in some centres despite the lack of guidelines for optimal use of this test...
  5. ncbi request reprint An update on therapeutic drug monitoring for antiretroviral drugs
    David Back
    Pharmacology Research Laboratories, University of Liverpool, 70 Pembroke Street, Liverpool, USA
    Ther Drug Monit 28:468-73. 2006
    ..Finally the development of the inhibitory quotient (IQ) concept is discussed...
  6. ncbi request reprint Pharmacokinetic drug interactions with nevirapine
    David Back
    Liverpool HIV Pharmacology Group, Pharmacology Research Laboratories, University of Liverpool, Pembroke Place, Liverpool L69 3GF, UK
    J Acquir Immune Defic Syndr 34:S8-14. 2003
    ..g. methadone, oral contraceptives, rifampicin, and there are some definite contraindications. By understanding pharmacological principles, it is possible to optimise use of multi-drug regimens...
  7. ncbi request reprint Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients
    Jennifer Ford
    Department of Pharmacology and Therapeutics, University of Liverpool, 70 Pembroke Place, Liverpool L69 3GF, and PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    J Antimicrob Chemother 58:1009-16. 2006
    ..To examine cellular and plasma concentrations of atazanavir when given in combination with saquinavir/ritonavir in HIV+ patients...
  8. doi request reprint Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach
    Marco Siccardi
    Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, 70 Pembroke Place, Liverpool, L69 3GF, UK
    Clin Pharmacokinet 52:583-92. 2013
    ....
  9. ncbi request reprint Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals
    Laura Dickinson
    Department of Pharmacology, University of Liverpool, Liverpool, UK
    Ther Drug Monit 29:361-7. 2007
    ..It may also aid the choice of sampling times for population analysis...
  10. pmc Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies
    Alessandro Schipani
    Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
    J Acquir Immune Defic Syndr 62:60-6. 2013
    ..Simulations of ATV concentration-time profiles were performed at doses of ATV/RTV 300/50 mg, 200/50 mg, and 200/100 mg once daily...
  11. pmc Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals
    Akil Jackson
    St Stephen s Centre, Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 58:450-7. 2011
    ..To investigate the pharmacokinetics of darunavir/ritonavir and raltegravir, in HIV-infected subjects, in both plasma and at the intracellular (IC) site of action...
  12. doi request reprint New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals
    Kay Seden
    NIHR Biomedical Research Centre, Royal Liverpool and Broadgreen University Hospitals Trust, and Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
    J Antimicrob Chemother 65:1079-85. 2010
    ..Therapeutic drug monitoring is likely to play a role in the clinical management of such interactions...
  13. pmc Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies
    Laura Dickinson
    Department of Pharmacology, University of Liverpool, Pharmacology Research Laboratories, Block H, First Floor, 70 Pembroke Place, Liverpool L693GF, United Kingdom
    Antimicrob Agents Chemother 55:2775-82. 2011
    ..The model allows a better understanding of the interaction between lopinavir and ritonavir and may allow a better prediction of lopinavir concentrations and assessments of different dosing strategies...
  14. doi request reprint Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions
    Kay Seden
    NIHR Biomedical Research Centre, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK
    Curr Opin HIV AIDS 6:514-26. 2011
    ..Potential for DDIs with the DAAs in clinical development and the mechanisms of interaction are also discussed...
  15. doi request reprint Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical Diseases
    Kay Seden
    aDepartment of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool bLondon Deanery Paediatrics Trainee, London, UK cInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda dDepartment of Pharmacology and Therapeutics, Trinity College Dublin eCenter for Global Health, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    AIDS 27:675-86. 2013
    ..It is intended to serve as a resource for policy makers and clinicians caring for these patients, and to support the recent WHO 2020 Roadmap and the 2012 London Declaration on NTDs...
  16. pmc Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC
    Wai San Kwan
    Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
    Br J Clin Pharmacol 68:375-80. 2009
    ..Darunavir is the most recently licensed protease inhibitor and we sought to investigate the ability of transport inhibitors to influence its intracellular accumulation in lymphocytes from healthy volunteers...
  17. pmc Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients
    Jennifer Ford
    Department of Pharmacology and Therapeutics, University of Liverpool, 70 Pembroke Pl, Block H, First Floor, Liverpool L69 3GF, United Kingdom
    Antimicrob Agents Chemother 48:2388-93. 2004
    ..The intracellular t(1/2)s of saquinavir and ritonavir were longer than the plasma t(1/2)s, indicating that intracellular drug may be available at a time when concentrations in plasma are below the minimum effective concentration...
  18. doi request reprint Pharmacokinetic evaluation of etravirine
    Laura Dickinson
    Royal Liverpool and Broadgreen University Hospital Trust, NIHR Biomedical Research Centre, Liverpool, UK
    Expert Opin Drug Metab Toxicol 6:1575-85. 2010
    ..Development of antiretrovirals active against resistant virus, such as the diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine, is important to broaden treatment options to patients who have few available...
  19. doi request reprint Pharmacokinetics and drug-drug interactions of antiretrovirals: an update
    Laura Dickinson
    NIHR Biomedical Research Centre, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK
    Antiviral Res 85:176-89. 2010
    ..org, http://www.clinicaloptions.com/hiv, http://hivinsite.ucsf.edu. This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010...
  20. doi request reprint Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds
    Laura Else
    Department of Pharmacology and Therapeutics, University of Liverpool, Pharmacology Research Laboratories, Liverpool, UK
    J Chromatogr B Analyt Technol Biomed Life Sci 878:1455-65. 2010
    ..The method described is being successfully applied to measure plasma antiretroviral concentrations from samples obtained from clinical pharmacokinetic studies...
  21. ncbi request reprint Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters
    Bridget Maher
    Department of Pharmacology, University of Liverpool, Liverpool, UK
    Antivir Ther 9:879-87. 2004
    ..To evaluate the effects of stopping treatment with protease inhibitors (PIs) on tumour necrosis factor (TNF)-alpha and TNF-receptor levels, and on the metabolic and morphological abnormalities seen in patients with lipodystrophy...
  22. doi request reprint Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting
    Kay Seden
    NIHR Biomedical Research Centre, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK
    J Antimicrob Chemother 68:1-3. 2013
    ....
  23. ncbi request reprint Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry
    Laura Dickinson
    Department of Pharmacology, University of Liverpool, Pharmacology Research Laboratories, Block H, First Floor, 70 Pembroke Place, Liverpool L69 3GF, UK
    J Chromatogr B Analyt Technol Biomed Life Sci 829:82-90. 2005
    ..The bioanalytical method described is successfully applied to measure PI concentrations obtained from clinical pharmacokinetic studies and routine therapeutic drug monitoring (TDM)...
  24. doi request reprint Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable
    Kay Seden
    NIHR Biomedical Research Centre, Royal Liverpool and Broadgreen University Hospitals Trust, Liverpool, UK
    J Antimicrob Chemother 64:5-8. 2009
    ....
  25. doi request reprint Grapefruit-drug interactions
    Kay Seden
    NIHR Biomedical Research Centre, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK
    Drugs 70:2373-407. 2010
    ..The aim of this review is to outline the mechanisms of grapefruit-drug interactions and present a comprehensive summary of those agents affected and whether they are likely to be of clinical relevance...
  26. ncbi request reprint The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro
    Becky Chandler
    University of Liverpool, Liverpool, United Kingdom
    J Acquir Immune Defic Syndr 33:551-6. 2003
    ..These results indicate the potential of some PIs and NNRTIs to induce P-gp expression in PBMCs in vitro...
  27. ncbi request reprint Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons
    Laura Dickinson
    Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
    Curr Opin HIV AIDS 3:296-305. 2008
    ..Physiological changes resulting from HIV disease can influence drug pharmacokinetics and the underlying mechanisms remain to be elucidated...
  28. doi request reprint Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells
    Philip Martin
    Department of Pharmacology and Therapeutics, The University of Liverpool, Pembroke Place, Liverpool, UK
    Acta Pharmacol Sin 31:51-65. 2010
    ....
  29. ncbi request reprint Therapeutic drug monitoring
    David Back
    J Int Assoc Physicians AIDS Care (Chic) 1:84-5. 2002
  30. ncbi request reprint Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication
    Wolfgang Stöhr
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 13:675-85. 2008
    ..The aim of this study was to examine factors influencing plasma concentration of efavirenz and nevirapine...
  31. doi request reprint HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options
    Jane E Mallewa
    Department of Infectious Diseases, North Manchester General Hospital, Delaunays Road, Manchester M8 5RB, UK
    J Antimicrob Chemother 62:648-60. 2008
    ..Some new approaches including adipocytokines, uridine supplementation, glitazones, growth hormone (or growth hormone-releasing hormone analogues), metformin and statins (used alone or in combination) merit further investigation...
  32. ncbi request reprint Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients
    Lauro J Waters
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    Antivir Ther 12:825-30. 2007
    ..This study investigated the steady-state plasma pharmacokinetics of abacavir when co-administered with atazanavir/ritonavir or lopinavir/ritonavir in HIV-infected individuals...
  33. ncbi request reprint Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics
    Martina Hennessy
    Department of Pharmacology and Therapeutics, Trinity College, Dublin, Ireland
    Antivir Ther 8:191-8. 2003
    ..To determine intracellular concentrations of indinavir (IDV) and investigate the relationship between plasma and intracellular IDV pharmacokinetics in HIV-infected patients...
  34. ncbi request reprint Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
    Alan Winston
    Department of Genitourinary and HIV Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    AIDS 18:572-4. 2004
    ..It was found that when changing from efavirenz to nevirapine individuals should commence on 200 mg twice a day, as this dose is associated with therapeutic plasma drug levels...
  35. pmc Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects
    Marta Boffito
    PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    Br J Clin Pharmacol 59:38-42. 2005
    ..To investigate whether the administration of tenofovir diproxil fumarate 300 mg once daily alters the plasma pharmacokinetics of the saquinavir hard gel/ritonavir combination in HIV-1 infected individuals...
  36. ncbi request reprint Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 10:375-92. 2005
    ..In addition, the panel formulated a series of position statements that are relevant to the interpretation of current data and can aid the design of future clinical trials...
  37. ncbi request reprint Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients
    Marta Boffito
    PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    J Acquir Immune Defic Syndr 37:1376-84. 2004
    ..This study evaluated the steady-state pharmacokinetics of saquinavir 1000 mg twice daily (bid) and fosamprenavir 700 mg bid administered with 2 different doses of ritonavir (100 and 200 mg bid) in HIV-1-infected subjects...
  38. ncbi request reprint Stopping antiretroviral therapy
    Stephen Taylor
    Directorate of Sexual Medicine and HIV, Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Bordesly Green East, Birmingham, UK
    AIDS 21:1673-82. 2007
  39. ncbi request reprint Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 10:469-77. 2005
    ....
  40. ncbi request reprint Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses
    Marta Boffito
    Chelsea and Westminster Hospital, London, United Kingdom
    AIDS Res Hum Retroviruses 22:749-56. 2006
    ..Atazanavir-related hyperbilirubinemia was dose dependent. However, higher saquinavir and atazanavir exposure may be required to suppress HIV-resistant strain replication...
  41. ncbi request reprint Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers
    Alan Winston
    Chelsea and Westminster Hospital, London, UK
    AIDS 20:1401-6. 2006
    ..We evaluated the effect of omeprazole, a proton-pump-inhibitor, on the pharmacokinetics of the recently developed saquinavir-500 mg formulation co-administered with ritonavir...
  42. ncbi request reprint Intracellular carbovir triphosphate levels in patients taking abacavir once a day
    Marianne Harris
    AIDS 16:1196-7. 2002
  43. ncbi request reprint Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 9:423-9. 2004
    ..To evaluate the steady-state pharmacokinetics and safety of two once-daily saquinavir/ritonavir (SQV/RTV) regimens, 1600/100 and 2000/100 mg, in HIV-positive patients...
  44. ncbi request reprint Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily
    Marta Boffito
    PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    J Antimicrob Chemother 55:542-5. 2005
    ..This study examined the pharmacokinetics of twice-daily saquinavir-hg (1000 mg) in the presence of ritonavir 100 mg, dosed twice-daily and once-daily on one single occasion...
  45. ncbi request reprint Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients
    Martina Hennessy
    Department of Pharmacology and Therapeutics, Trinity College Dublin, Dublin, Ireland
    Antivir Ther 9:115-22. 2004
    ..To compare plasma and intracellular nelfinavir pharmacokinetics, and determine their relationship to P-glycoprotein (P-gp) expression and function in lymphocytes of HIV-infected patients...
  46. ncbi request reprint Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL, and CEM E1000 cells
    Andrew Owen
    J Infect Dis 187:874-5; author reply 875-6. 2003
  47. ncbi request reprint The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA
    David M Margolis
    Department of Medicine, Division of Infectious Diseases, North Texas Veterans Health Care Systems, Dallas, USA
    J Acquir Immune Defic Syndr 31:45-9. 2002
    ..The possibility that MMF may enhance the effect of selected NRTIs and be tolerated in late stage HIV disease deserves careful randomized study...
  48. ncbi request reprint The potential for interactions between antimalarial and antiretroviral drugs
    Saye Khoo
    AIDS 19:995-1005. 2005